Cambridge Healthtech Institute’s inaugural

Targeted Radioligand Therapies

Precision Medicine for Cancer

January 14-15, 2025

Targeted radiotherapies, also known as radioligand therapies or molecular radiotherapy, represent a promising frontier in cancer treatment. By combining the specificity of targeted molecules with the potency of radioisotopes, these therapies offer the potential for precise and effective cancer cell elimination while minimizing damage to healthy tissues. At Cambridge Healthtech Institute's Targeted Radioligand Therapies track, we will explore the latest advancements, challenges, and opportunities in this rapidly evolving field, fostering collaborations among researchers, clinicians, and industry leaders to drive the development of these innovative treatments. Attendees will gain insights into innovative targeting mechanisms, radioisotope selection, emerging targets, clinical updates, combination strategies, and logistics and supply chain challenges, culminating in discussions to accelerate the translation of these precision therapies to the clinic.

Novel Targeting Mechanisms and Vectors

Peptides, antibodies, and small molecules for targeted delivery
Alternative scaffolds: DARPins, affibodies, bicycles, and nanobodies
Bispecific and multispecific approaches
Strategies for improving tumor penetration and binding affinity

Emerging Targets and Indications

Exploration of novel targets beyond PSMA and somatostatin receptors
Expanding applications to different cancer types (e.g., breast, lung, glioblastoma)
Potential for non-oncology indications

Radiochemistry, Radiobiology and Isotope Landscape

Alpha vs Beta emitters, and emerging isotopes
Advancements in radiolabeling techniques and radiochemistry
Mechanisms of radiation-induced cell death and tumor microenvironment modulation
Strategies for enhancing therapeutic efficacy and overcoming resistance

Clinical Trials, Regulatory Landscape and Patient Management

Ongoing clinical trials for various cancer types (e.g., prostate, neuroendocrine tumors)
Regulatory considerations and approval pathways
Patient selection, dosimetry, and treatment planning
Combination Strategies - radioligand therapies combined with immunotherapy, chemotherapy, or targeted agents
Overcoming resistance mechanisms and tumor heterogeneity
Toxicity management

Theranostics and Companion Diagnostics

Integration of diagnostic imaging and targeted therapy
Development of companion diagnostics for patient stratification
Biomarkers for predicting treatment response
Personalized dosimetry and treatment planning

Manufacturing and Supply Chain Considerations

Radioisotope supply chain and availability challenges
Radiopharmaceutical production and quality control
Logistics and distribution challenges for short-lived radioisotopes

The deadline for priority consideration is June 28, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: